Dr. Glaspy on Immunotherapy in Endometrial Cancer

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles School of Medicine, discusses immunogenicity in endometrial cancer.

Immunotherapy has had a big impact on patients with endometrial cancer. Glaspy states that patients with endometrial cancer are going to need to have access to the same sort of combinatorial trials as those that are available to patients with ovarian cancer.

Tumor mutational burden (TMB) analyses tend to be on the low end of the spectrum, as in ovarian cancer, says Glaspy. Therefore, the subset of patients with clear-cell disease would be a good place to focus because they have a higher TMB.

There are ongoing combinatorial immunotherapy trials for patients with endometrial cancer. There are trials that are open to patients with all tumor types, and those specifically enrolling patients with endometrial cancer, states Glaspy.